Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

NCT01467661 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Thrombocythemia (ET)

Interventions

DRUG: SPD422 (anagrelide hydrochloride)

Sponsor

Shire